While many celebrated the FDA approval of Descovy for PrEP earlier this month, advocates wonder whether it will make biomedical HIV prevention more or less accessible to those most in need.
Generic pre-exposure prophylaxis (PrEP) is available in at least 26 countries, allowing those countries to scale up access and reduce HIV transmissions. Why not here?
The PrEP Access and Coverage Act would guarantee insurance coverage for PrEP and fund PrEP for the uninsured.
"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."
Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.
The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.
Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.
But a survey reveals that about a third of black and Latino gay men would be willing to pay more than $50 per month for a prescription.
In a debate during a plenary session, Michael Saag, M.D., argued for more activism to make PrEP accessible to people who need it.
"A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified -- cost shouldn't be one of them," write James Krellenstein and Jeremiah Johnson.